All News

shoulder.exam_.jpg

Outpatient Visits Return to Pre-COVID Rates

d Jack Cush, MD

The COVID-19 pandemic dramatically impacted outpatient care - numbers, scope, quality, etc, but a recent study suggests that while COVID has changed the scope of care, the numbers of outpatient visits have risen to near pre-pandemic numbers.

Read Article
choices2.jpg

TNF Inhibitors or non-TNF Biologics - First Best Choice?

d Jack Cush, MD

Prospective observational findings from the CORRONA registry of rheumatoid arthritis (RA) patients compared clinical outcomes between initial aggressive therapy using either a tumour necrosis factor inhibitor (TNFi) or a non-TNFi (biological disease-modifying antirheumatic drugs (bDMARDs) and tar

Read Article
FDA2.jpg

FDA Warning on NSAIDs in Pregnancy

d FDA

The U.S. Food and Drug Administration announced today in a Drug Safety Communication that it is requiring labeling changes for nonsteroidal anti-inflammatory drugs (NSAIDs).

Read Article
podcast logo

RheumNow Podcast – Good Time Charlie…. (10.16.20)

d Jack Cush, MD

Dr. Jack Cush sings the news and journal reports from the past week on RheumNow.com.

Read Article
UPA ABA box

Abatacept vs. Upadacitinib in Biologic Refractory Rheumatoid Arthritis

d Jack Cush, MD

NEJM reports the results of the SELECT-Choice trial, a head to head study of upadacitinib (UPA) and abatacept (ABA) in biologic refractory rheumatoid arthritis (RA); 12 weeks results showed UPA was significantly more clinically effective than ABA using a DAS28-CRP remission, but ABA had fewer safety signals and serious adverse events.

Read Article
Cancer.risk_.jpg

ICI Arthritis Tied to Cancer Progression

d

Cancer patients treated with immune checkpoint inhibitors (ICI) who develop severe arthritis may be at risk for progression of the malignancy, a single-center study suggested.

Read Article
Lilly has announced results of Phase 2 SERENITY trial showing the IL-23 inhibitor, mirikizumab, was more effective than PBO at week 12 (PRO and endoscopic outcomes) in moderate to severe active Crohn's disease. Efficacy continued out to week 52 https://t.co/n8Mdeonmas

Links:

Dr. John Cush RheumNow ( View Tweet)

SELECT CHOICE, H2H study of UPA vs ABA in TNF-IR RA pts; UPA had better DAS28-CRP & ABA had better Safety outcomes; Which would you use?

Dr. John Cush RheumNow ( View Tweet)

Not sure why this study was done...BUT... Tociiizumab was studied in 104 hand osteoarthritis and after 12 weeks, TCZ was equivalent to Placebo in achieving100mm VAS pain reduction (-9.9 vs -7.9), but TCZ had numerically more adverse events https://t.co/NYujNQbjvm

Links:

Dr. John Cush RheumNow ( View Tweet)

QD Clinics - Vignette Lessons from Rheum Clinic. Week 2: choosing IL-1 inhibitors, burnt out RA or not RA, trigger fingers, peripheral SpA, Gout or not? Listen on iTunes https://t.co/FHJv01Sb3a or on Android https://t.co/V488PY9lIo

Links:

Dr. John Cush RheumNow ( View Tweet)

Congratulations to Carlos J. Lozada, MD, recipient of the 2020 Distinguished Fellowship Program Director Award! @UMiamiHealth #ACR20 https://t.co/OsiChNSbjn
American College of Rheumatology ACRheum ( View Tweet)
Looking forward to Cool Comedy Hot Cuisine with @bobsaget tomorrow evening - supporting #scleroderma research. This year the event is online - join us wherever you are! @srfcure https://t.co/2iuRKOKk3J

Links:

Victoria Shanmugam VickiShanmugam ( View Tweet)

(Ethic)Efficacy of tocilizumab in patients with hand osteoarthritis: double blind, randomised, placebo-controlled, multicentre trial https://t.co/7k7p6HJ4Ni #tocilizumab #OAhands another one bites the dust!

Links:

Peter Nash drpnash ( View Tweet)

SELECT CHOICE, H2H study of UPA vs ABA in TNF-IR RA pts; UPA had better DAS28-CRP & ABA had better Safety outcomes; Which would you use?

Dr. John Cush RheumNow ( View Tweet)

QD Clinics - Vignette Lessons from Rheum Clinic - Compilation on No Shows, Delays in SpA Dx, & when patients bail out on DMARD therapy. Listen on iTunes https://t.co/FHJv01AAbC on on Android> https://t.co/i8icH8AS9m

Links:

Dr. John Cush RheumNow ( View Tweet)

Pre Print of UK research suggests biomarkers for Severe COVID-19 includes markers of myeloid or endothelial activation; such as D-dimer, EN-RAGE, CXCL10, GM-CSF, IL-6, TNF-α, IL-2, GDF-15, G-CSF, S100A12, https://t.co/Yv6yM4DYmp

Links:

Dr. John Cush RheumNow ( View Tweet)

259 SLE patients followed an 80% were in lupus low disease activity state (LLDAS); 82% in remission; 19% w/ active dz. 56 pst in subjective Low activity (SLQ<6) compared to SLAQ>6, latter had more arthritis, fibromyalgia and took steroids https://t.co/IdeSNlaEOG

Links:

Dr. John Cush RheumNow ( View Tweet)

Juvenile localized scleroderma was Rx w/ MTX or MMF (in MTX refractory) and compared retrospectively. Facial linear scler. more likely in MTX pts and MMF pts had pansclerotic morphea or mixed subtype. Outcomes were same at 9.4 yrs: inactive in 100% & 91% https://t.co/2X9SpqeLwx

Links:

Dr. John Cush RheumNow ( View Tweet)

EUSTAR study of ILD in systemic sclerosis: 826 pts with SSc-ILD finds 27% with progressive ILD (mod-severe FVC decline >5-10%) over 12 mos. Predictive factors for FVC decline over 5 yrs were male sex, higher mRSS skin score and reflux/dysphagia symptoms. https://t.co/lLd2FrMIkx

Links:

Dr. John Cush RheumNow ( View Tweet)

@MattieRheumMD @News_CRA @statnews People are being crushed by co-pays- rheumatology patients' co-pays doubled to $1000 last year - and medical staff are wasting much time on paperwork. Plus, the @Aetna @CVSHealth merger caused prior auth meltdown in many. (Intentional?) Rebate system must go! ASK STAKEHOLDERS.

Angus Worthing MD AngusWorthing ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×